Clinical trial
A Randomized, International, Multi Centre Study to Assess the Efficacy and Safety of Intravenous PEG-liposomal Prednisolone Sodium Phosphate (Nanocort®) vs Intravenous Methylprednisolone (Solu-Medrol®) Treatment in Patients With Acute Exacerbation of Relapsing-remitting Multiple Sclerosis or in Patients With Clinically Isolated Syndrome (CIS)
NCT01039103 is registered in ClinicalTrials.gov with Lakefront Biotherapeutics NV as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, International, Multi Centre Study to Assess the Efficacy and Safety of Intravenous PEG-liposomal Prednisolone Sodium Phosphate (Nanocort®) vs Intravenous Methylprednisolone (Solu-Medrol®) Treatment in Patients With Acute Exacerbation of Relapsing-remitting Multiple Sclerosis or in Patients With Clinically Isolated Syndrome (CIS)
- Lead sponsor
- Lakefront Biotherapeutics NV
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- December 31, 2009
- Completion date
- November 30, 2011
- Enrollment
- 15 (actual)
- Sites
- 8
Conditions
As the registry lists them; a condition with its own page is linked.
acute exacerbation of remitting relapsing multiple sclerosis, clinically isolated syndrome